Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Altamira Therapeutics ( (CYTO) ) just unveiled an announcement.
Altamira Therapeutics announced its transition from Nasdaq to the OTCQB marketplace after failing to comply with Nasdaq’s minimum bid price requirement. The move ensures that trading of its shares continues uninterrupted under the ticker ‘CYTOF’, with no reverse stock split needed. Altamira’s CEO expressed disappointment but emphasized the opportunities presented by joining the OTCQB, a large marketplace for emerging growth companies, which aligns with their focus on expanding their RNA delivery platforms.
More about Altamira Therapeutics
Altamira Therapeutics is a company focused on developing and supplying peptide-based nanoparticle technologies for RNA delivery to extrahepatic tissues, with its proprietary platforms OligoPhore™ and SemaPhore™. The company is working on preclinical siRNA programs for KRAS driven cancer and rheumatoid arthritis and offers its versatile delivery platform for licensing. Altamira is also involved in the commercialization of Bentrio®, a nasal spray for allergic rhinitis, and is headquartered in Hamilton, Bermuda, with main operations in Basel, Switzerland.
YTD Price Performance: -91.38%
Average Trading Volume: 124,674
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $1.13M
See more data about CYTO stock on TipRanks’ Stock Analysis page.
